Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.45 |
| ▸ | PLD1 | Q13393 | 5/20 | 0.43 |
| ▸ | PLD2 | O14939 | 3/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834124 | 1.00 | HRH3 (0.48) | HRH3HRH4CHRM2CHRM4CHRM1 | |
| SCHEMBL30834075 | 0.88 | CHRM2 (0.49) | CHRM2CHRM4CHRM1CHRM3OPRM1 | |
| SCHEMBL27201378 | 0.88 | CHRM2 (0.49) | CHRM2CHRM4CHRM1CHRM3OPRM1 | |
| SCHEMBL27201309 | 0.76 | HRH3 (0.51) | HRH3HRH4 | |
| SCHEMBL30885237 | 0.76 | HRH3 (0.51) | HRH3HRH4 | |
| SCHEMBL27201377 | 0.76 | HRH4 (0.51) | HRH3HRH4OPRM1OPRL1FAAH | |
| SCHEMBL30834264 | 0.76 | HRH4 (0.51) | HRH3HRH4OPRM1OPRL1FAAH | |
| SCHEMBL30834227 | 0.74 | HRH3 (0.50) | HRH3HRH4 | |
| SCHEMBL30885213 | 0.74 | HRH3 (0.50) | HRH3HRH4 | |
| SCHEMBL27201453 | 0.74 | HRH3 (0.50) | HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | claimed |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | HRH3 4300/4885HRH4 4074/4885CHRM2 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.